High-throughput sequencing of natively paired antibody chains provides evidence for original antigenic sin shaping the antibody response to influenza vaccination

Clinical Immunology

Volumn 151, Issue 1, 2014, Pages 55-65

  Tan, Yann Chong ^a,b,c   Blum, Lisa K ^a,b   Kongpachith, Sarah ^a,b,c   Ju, Chia Hsin ^a,b   Cai, Xiaoyong ^a,b   Lindstrom, Tamsin M ^a   Sokolove, Jeremy ^a,b   Robinson, William H ^a,b,c  

^a STANFORD UNIVERSITY   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody; ; B cell; Influenza;

Indexed keywords

ANTIBODY;; B CELL; INFLUENZA;;

AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; B-LYMPHOCYTES; HEMAGGLUTININS, VIRAL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H1N2 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MOLECULAR SEQUENCE DATA; MOLECULAR TYPING; VACCINATION; VACCINES, SUBUNIT;

EID: 84893776492     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.12.008     Document Type: Article

References (41)

1. Molinari N.A., et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007, 25(27):5086-5096.
2. Yewdell J.W., et al. Getting to the heart of influenza. Sci. Transl. Med. 2013, 5(191):191. (ed8).
3. Barry J.M. Pandemics: avoiding the mistakes of 1918. Nature 2009, 459(7245):324-325.
4. Ahmed R., Oldstone M.B., Palese P. Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nat. Immunol. 2007, 8(11):1188-1193.
5. Osterholm M.T., et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 2012, 12(1):36-44.
6. Goodwin K., Viboud C., Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006, 24(8):1159-1169.
7. Nabel G.J. Designing tomorrow's vaccines. N. Engl. J. Med. 2013, 368(6):551-560.
8. Sasaki S., et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J. Clin. Invest. 2011, 121(8):3109-3119.
9. Jiang N., et al. Lineage structure of the human antibody repertoire in response to influenza vaccination. Sci. Transl. Med. 2013, 5(171):171. (ra19).
10. Vollmers C., et al. Genetic measurement of memory B-cell recall using antibody repertoire sequencing. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(33):13463-13468.
11. Li Y., et al. Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J. Exp. Med. 2013, 210(8):1493-1500.
12. Li G.M., et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(23):9047-9052.
13. Chiu C., et al. Cross-reactive humoral responses to influenza and their implications for a universal vaccine. Ann. N. Y. Acad. Sci. 2013, (1283):13-21. 10.1111/nyas.12012.
14. Wrammert J., et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 2011, 208(1):181-193.
15. ORIGINAL antigenic sin. N. Engl. J. Med. 1958, 258(20):1016-1017.
16. Wrammert J., et al. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J. Virol. 2012, 86(6):2911-2918.
17. Wrammert J., et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008, 453(7195):667-671.
18. Fink K. Origin and function of circulating plasmablasts during acute viral infections. Front. Immunol. 2012, 3:78.
19. Radbruch A., et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 2006, 6(10):741-750.
20. He X.S., et al. Plasmablast-derived polyclonal antibody response after influenza vaccination. J. Immunol. Methods 2011, 365(1-2):67-75.
21. Moir S., Fauci A.S. Insights into B cells and HIV-specific B-cell responses in HIV-infected individuals. Immunol. Rev. 2013, 254(1):207-224.
22. Alamyar E., et al. IMGT/HighV-QUEST: the IMGT(R) web portal for immunoglobulin (IG) or antibody and T cell receptor (TR) analysis from NGS high throughput and deep sequencing. Immunome Res. 2012, 8(1):26.
23. Edgar R.C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004, 32(5):1792-1797.
24. Guindon S., et al. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst. Biol. 2010, 59(3):307-321.
25. Huerta-Cepas J., Dopazo J., Gabaldon T. ETE: a python environment for tree exploration. BMC Bioinforma. 2010, 11:24.
26. Schmidt W.M., Mueller M.W. CapSelect: a highly sensitive method for 5' CAP-dependent enrichment of full-length cDNA in PCR-mediated analysis of mRNAs. Nucleic Acids Res. 1999, 27(21):e31.
27. Victora G.D., Nussenzweig M.C. Germinal centers. Annu. Rev. Immunol. 2012, 30:429-457.
28. McKean D., et al. Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. Proc. Natl. Acad. Sci. U. S. A. 1984, 81(10):3180-3184.
29. Sablitzky F., Wildner G., Rajewsky K. Somatic mutation and clonal expansion of B cells in an antigen-driven immune response. EMBO J. 1985, 4(2):345-350.
30. Good K.L., Tangye S.G. Decreased expression of Kruppel-like factors in memory B cells induces the rapid response typical of secondary antibody responses. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(33):13420-13425.
31. Tangye S.G., et al. Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses. J. Immunol. 2003, 170(2):686-694.
32. Kaur K., Sullivan M., Wilson P.C. Targeting B cell responses in universal influenza vaccine design. Trends Immunol. 2011, 32(11):524-531.
33. Labrosse B., et al. Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 influenza viruses using a pseudotype neutralization assay. PLoS One 2010, 5(6):e11036.
34. Wei C.J., et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010, 329(5995):1060-1064.
35. He X.S., et al. Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine. J. Infect. Dis. 2013, 207(2):288-296.
36. Francis T.J. On the doctrine of original antigenic sin. Proc. Am. Philos. Soc. 1960, 104(6):572-578.
37. Fischer N. Sequencing antibody repertoires: the next generation. MAbs 2011, 3(1):17-20.
38. Mathonet P., Ullman C.G. The application of next generation sequencing to the understanding of antibody repertoires. Front. Immunol. 2013, 4:265.
39. Reddy S.T., et al. Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells. Nat. Biotechnol. 2010, 28(9):965-969.
40. Cheung W.C., et al. A proteomics approach for the identification and cloning of monoclonal antibodies from serum. Nat. Biotechnol. 2012, 30(5):447-452.
41. DeKosky B.J., et al. High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire. Nat. Biotechnol. 2013, 31(2):166-169.